Platelet-Rich Plasma Injection for Thumb Carpometacarpal Joint Osteoarthritis

Area of Science:

• Orthopedics
• Regenerative Medicine
• Musculoskeletal Disorders

Background:

• Thumb carpometacarpal (CMC) joint osteoarthritis (OA) is a common cause of hand pain and dysfunction.
• Platelet-rich plasma (PRP) is an autologous blood derivative containing high concentrations of platelets and growth factors, with potential therapeutic applications in OA.

Purpose of the Study:

• To evaluate the efficacy and safety of platelet-rich plasma (PRP) injections for managing thumb carpometacarpal (CMC) joint osteoarthritis (OA).

Main Methods:

• Retrospective chart review of 19 adult patients who received PRP injections for thumb CMC joint OA between 2015 and 2020.
• Patient-reported outcomes, including symptom improvement (visual analog scale), duration of benefit, satisfaction, and adverse events, were collected via questionnaires and surveys.

Main Results:

• 68.8% of injected joints reported moderate to excellent symptom improvement.
• The mean reported duration of benefit was 15.6 months.
• No major complications were reported; 68.8% of patients were moderately to very satisfied with the procedure.

Conclusions:

• PRP injection is a potentially safe and effective treatment for pain associated with first CMC joint OA.
• Further research is warranted to optimize PRP treatment protocols and identify patient subgroups most likely to benefit.